Intrexon, Histogenics deal
Intrexon granted Histogenics access to technologies to develop allogeneic genetically modified chondrocyte cell therapeutics to repair damaged articular hyaline cartilage. The partners plan to design and manufacture next-generation cartilage tissue products that integrate Histogenics' cellular scaffold platforms and manufacturing processes. The companies will use Intrexon's UltraVector platform for gene program design plus the company's cell substrates and cell engineering technologies. The UltraVector platform is an operating system comprising advanced DNA construction technologies, cellular and protein engineering, computational models and statistical methods which facilitate the rapid design, testing and production of complex biological systems. ...